| Identification | Back Directory | [Name]
Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1) | [CAS]
1784253-05-9 | [Synonyms]
CZC-54252 HCl
Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1)
CZC 54252,CZC54252 hydrochloride,injury,inhibit,LRRK2,CZC54252,CZC-54252,neuronal,Leucine-rich repeat kinase 2,neuroprotective,Inhibitor,CZC 54252 hydrochloride,LRRK2-G2019S | [Molecular Formula]
C22H26Cl2N6O4S | [MOL File]
1784253-05-9.mol | [Molecular Weight]
541.45 |
| Chemical Properties | Back Directory | [storage temp. ]
-20° | [solubility ]
Soluble in DMSO (up to 50 mg/ml). | [form ]
solid | [color ]
Off-white | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
| Hazard Information | Back Directory | [Description]
CZC-54252 HCl (1784253-05-9) is a novel, potent and selective inhibitor of the leucine-rich repeat kinase-2 (LRRK2), IC50 = 1.28 nM. Also inhibits G2019S mutant LRRK2, IC50 = 1.85 nM.1?CZC-54252 attenuates the neuronal damage elicited by the action of LRRK2 G2019S mutant in primary human neurons (EC50 = 1 nM).1 The G2019S mutant is a common mutation found in familial Parkinson’s disease patients.2?Cell permeable. | [References]
1) Ramsden et al. (2011), Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons; ACS Chem. Biol., 6 102
2) Kramer et al. (2012), Small molecule kinase inhibitors for LRRK2 and their application to Parkinson’s disease models; ACS Chem. Neurosci., 3 151 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|